Dual CTLA-4 and PD-1 Checkpoint Blockade Using CS1002 and CS1003 (nofazinlimab) in Patients with Advanced Solid Tumors: A First-in-human, Dose-Escalation, and Dose-Expansion Study

Sarwan Bishnoi,Dusan Kotasek,Morteza Aghmesheh,Thomas Yau,Rasha Cosman,Amy Prawira,Maggie Moore,Stephen L. Chan,Andrew Mant,Richard Eek, Robert Zielinski,Rila Su, Zhaoxuan Pan,Yiding Ma, Fei Li,Peiqi Li,Archie N. Tse

Cancer（2024）

引用 0|浏览27

关键词

anti-CTLA-4 monoclonal antibody,anti-programmed cell death protein 1 monoclonal antibody,CS1002,CS1003,microsatellite instability-high,mismatch repair-deficient

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要